Application of plantamajoside in preparing medicines for treating Parkinson's disease

A technology of psyllium and Parkinson's disease, applied in the field of medical use

Inactive Publication Date: 2018-10-12
CHENGDU INST OF BIOLOGY CHINESE ACAD OF S
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] At present, there is no drug that has a good therapeutic effect on Parkinson's disease. In view of this, this application is hereby proposed

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of plantamajoside in preparing medicines for treating Parkinson's disease
  • Application of plantamajoside in preparing medicines for treating Parkinson's disease

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0039] In vitro inhibitory activity of psyllogen on monoamine oxidase B (MAO-B):

[0040] 1. Experimental principle:

[0041] MAO-B catalyzes the substrate kynuramine to generate 4-hydroxyquinoline under suitable reaction conditions, and 4-hydroxyquinoline produces 400nm emission light under the excitation light of 310nm. By detecting the change of the fluorescence intensity at 310 / 400nm, the change of the production amount of the product was detected, and then the inhibitory effect of the inhibitor on MAO-B was calculated.

[0042] 2. Experimental materials:

[0043] Test article: great psyllidin;

[0044] Positive control: safinamide;

[0045] Enzyme source: purchased commercial MAO-B, stored at -20°C. Dilute it to the working solution concentration (9U / mL) with 12.5mM phosphate buffer solution (pH 7.4) immediately before use.

[0046] Test article and positive control treatment: dissolve in 12.5mM phosphate buffer solution (pH 7.4) containing 10% dimethyl sulfoxide, th...

experiment example 2

[0063] In vitro agonist activity of psyllogen on PINK1 protein kinase:

[0064] 1. Experimental principle

[0065] Ubiquitin is an effective substrate of PINK1. Under the activation of PINK1, ubiquitin will use ATP to phosphorylate and generate ADP. After ADP is derivatized with fluorescence, the amount of ADP generated can be detected by chemiluminescence, representing PINK1 For the activation of ubiquitin, according to the enzyme reaction rate method, the ADP generation rate can reflect the activity of PINK1.

[0066] 2. Experimental materials

[0067] Test article: great psyllidin;

[0068] Buffer: 40mM Tris-HCl (pH 7.5), 20mM MgCl 2 , 0.1mg / mL BSA;

[0069] Enzyme and ATP treatment: purchase, store at -80°C. Dilute to 0.25 μM before use.

[0070] Substrate: Construct a plasmid according to the ubiquitin nucleotide sequence queried on Genbank, transfect it into Escherichia coli BL21 for expression, purify it with Ni-IDA, store it at -80°C, and dilute it to 0.25 μM bef...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides an application of plantamajoside in preparing medicines for treating Parkinson's disease, and relates to the field of medical applications. Based upon researches, the inventor discovers that the plantamajoside is excellent in activity of inhibiting monoamine oxidase B; meanwhile, the plantamajoside also has agonist activity on PINK1 protein kinase, so that the plantamajosidecan simultaneously serve as an inhibitor of the monoamine oxidase B and an agonist of activity of the PINK1 protein kinase; the plantamajoside is expected to be developed into medicines for treatingsuch severe diseases as the Parkinson's disease, chronic obstructive pneumonia and the like; therefore, the plantamajoside has a broad application prospect.

Description

technical field [0001] The present invention relates to the field of medical applications, in particular to the application of psyllogen in the preparation of a drug for treating Parkinson's disease. Background technique [0002] Parkinson's disease (PD) is one of the most common neurodegenerative diseases clinically. The incidence of the disease presents a trend that is positively correlated with the increase of age, and the prevalence rate among people over 65 years old is 1.7%, and the prevalence increased to 4.8% in people older than 85 years. Its incidence rate is high, second only to Alzheimer's disease (Alzheimer's disease, AD). The clinical features of the disease are mainly resting tremor, muscle rigidity, abnormal gait and slow movement. infiltration. [0003] The etiology and pathogenesis of PD have not yet been definitively determined, and mainstream studies believe that it is a disease closely related to aging, environmental and genetic factors. With the dev...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7032A61P25/16A61P25/28A61P11/00A61P3/10A61P1/16A61P35/00
CPCA61K31/7032A61P1/16A61P3/10A61P11/00A61P25/16A61P25/28A61P35/00
Inventor 廖循吴桂芳袁韫聪
Owner CHENGDU INST OF BIOLOGY CHINESE ACAD OF S
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products